FDA Accepts Supplement for Vyvanse (NDA 208510) from Takeda
The FDA has accepted a supplemental application for Vyvanse (lisdexamfetamine dimesylate) from Takeda Pharmaceuticals.
Company
Pharmaceutical intelligence for Takeda with 12 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.